ClinicalTrials.gg
Active, not recruitingNCT07668245AQoLStrokeUpdated Oct 13, 2026

Effectiveness of Attention Focus Training on Attention and Quality of Life in Stroke

An interventional study of Exercise and Conventional in Stroke, sponsored by Shifa Tameer-e-Millat University. Active, not recruiting at 1 site in Pakistan. Open to participants aged Up to 55 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Shifa Tameer-e-Millat University · Not applicable, Interventional, and Treatment

Updated Oct 13, 2026Now Active, not recruitingStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
Up to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 333 studies in Stroke with a site in Pakistan — 103 open to participants now, 134 under way, 1 of them phase 3. Stroke · Pakistan.

Planned enrollment
132nd of 306
46 · median 42
Started
2026
with 52 others
No phase
300 of 333
99 open now
Primary completion
2026-09
later than 106 of 133 live
Registered
304th of 333
by date
Lead sponsor
7 of 333
Shifa Tameer-e-Millat University

Among the 333 studies in Stroke with a site in Pakistan, this one is the 132nd largest by planned enrollment of the 306 interventional ones that give a count, is one of 53 that started in 2026, is one of 300 with no phase, reaches primary completion later than 106 of the 133 other live ones, and was the 304th registered.

Stroke

8,269 studies on the registry are indexed under Stroke; 2,062 are open to participants now.

Browse Stroke studies →

Open to participants now

103 of the 333 studies in Stroke with a site in Pakistan are open now. Recruiting first, the newest first:

98 more — sign in →

All 103 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 1,419 Stroke studies recruiting now, 695 (49%) set no upper age limit and 283 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: Up to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 333 studies in Stroke with a site in Pakistan, or all of them as a file.
02

Study summary

This RCT will determine the effects of attention focus training which is a comprehensive intervention to improve cognitive outcomes. Attention is one of the major cognitive outcome and problems with attention can deteriorate the quality of life of people suffering from stroke. Intervention will be provided for 4 weeks. Outcomes will be assessed at baseline and after provision of intervention.

03

Conditions studied

  • Stroke

Browse trials for

Keywords

  • Attention
  • Quality of life
  • Stroke
04

Who can participate

Ages eligible
Up to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants diagnosed with stroke
  • Able to ambulate at least with assistance
  • Medically stable

Exclusion criteria

Exclusion Criteria:

  • Severe cognitive impairment ( \< 24)
  • Pre-existing dementia
  • Visual/hearing impairment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    Attention Focus Training with Conventional therapy

    The training group will address the four core components of attention: focus, sustained, selective and alternating attention. Additionally, conventional therapy for stroke will be given.

    Other: Exercise · Other: Conventional

  • Active comparator
    Conventional therapy

    Conventional therapy for stroke will be given

    Other: Conventional

Interventions

  • OtherExercise

    Focused attention (auditory target detection), Sustained attention (letter cancellation), Selective attention (cancellation with distractors), Alternating attention (number-letter switching)

  • OtherConventional

    Positioning and bed mobility, sitting balance training, standing training

06

What researchers measure

Primary outcomes

  1. Stroop Color-Word Test

    It consists of three conditions/sheets: (i) Word (W), in which the participant reads color words; (ii) Color (C), in which they name the ink colors; (iii) Color-Word (CW), in which they name the ink color while inhibiting the tendency to read the conflicting word. Responses are recorded and calculated for all three sheets. Scores are based on the number of correct responses within the specified time (45 minutes), with higher scores indicating better performance.

    Time frame: Baseline and post 4 weeks of intervention

  2. Trail Making Test Test (A & B)

    Trial Making Test (TMT) consists of two parts (TMT-A \& TMT-B). For TMT-A, participants connect numbers in sequential order (e.g. 1-2-3-4). For TMT-B, participants alternate between numbers and letters (e.g. 1-A-2-B-3-C). Participants are instructed to completed each task as quickly and accurately as possible. Score is primarily the time in seconds to complete the task. Lower time denotes better performance.

    Time frame: Baseline & post 4 weeks of intervention

  3. Stroke Impact Scale

    Stroke Impact Scale (SIS) scores range from 0 to 100 for each domain. A score of 0 indicates greatest impact of stroke or complete inability to perform tasks within that domain, while a score of 100 indicates no disability, no difficulty performing tasks, and the best possible outcome. Higher scores indicate better functioning and less impact of stroke.

    Time frame: Baseline and post 4 weeks of intervention

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2026 to primary completion in Sep 2026, 1 month.

Of 3,119 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's 1 month is below that.

Counting every sponsor, half of 3,263 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Aug 2026, on Oct 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2026
First posted
Jun 25, 2026
StartActual
Aug 1, 2026was Jul 2026
Primary completionActual
Sep 15, 2026
CompletionEst.
Oct 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Active, not recruiting
changed Oct 13, 2026
Start date
Jul 3, 2026→Aug 1, 2026 (actual)
Oct 13, 2026
Primary completion
Sep 3, 2026→Sep 15, 2026 (actual)
Oct 13, 2026
Primary outcomes
2 added, 1 removed
What changed in the outcomes
  • AddedStroop Color-Word TestTime frame: Baseline and post 4 weeks of intervention
  • AddedTrail Making Test Test (A & B)Time frame: Baseline & post 4 weeks of intervention
  • RemovedTest of Everyday AttentionTime frame: Baseline and post 4 weeks of intervention
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Not yet recruiting→Active, not recruiting
    Start date Jul 3, 2026→Aug 1, 2026 (now actual)
    Primary completion Sep 3, 2026→Sep 15, 2026 (now actual)
    Primary outcomes 2 added, 1 removed
    What changed in the outcomes
    • AddedStroop Color-Word TestTime frame: Baseline and post 4 weeks of intervention
    • AddedTrail Making Test Test (A & B)Time frame: Baseline & post 4 weeks of intervention
    • RemovedTest of Everyday AttentionTime frame: Baseline and post 4 weeks of intervention
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07668245
Lead sponsor
Shifa Tameer-e-Millat University
Responsible party
Shafaq Altaf (Assistant Professor, Shifa Tameer-e-Millat University) — Principal investigator
First posted
Jun 25, 2026
Start date
Aug 1, 2026
Primary completion
Sep 15, 2026
Completion
Oct 2026 (estimated)
Last update
Oct 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion